HNRNPA2B1:调控肺动脉高压中平滑肌细胞表型的RNA结合蛋白
该研究探讨RNA结合蛋白HNRNPA2B1(A2B1)在肺动脉高压(PAH)肺动脉平滑肌细胞(PASMC)表型调控中的作用。通过计算与实验生物学结合,发现A2B1在人类PAH-PASMC中表达及核定位增加,通过其识别的3个基序协调细胞周期相关mRNA表达,促进增殖和抗凋亡;沉默A2B1可降低靶mRNA并逆转表型,在大鼠模型中抑制A2B1可缓解肺动脉高压。
要点
- A2B1在人类PAH-PASMC中表达和核定位增加。
- A2B1通过3个已知基序协调PAH-PASMC细胞周期相关mRNA表达。
- 抑制A2B1可在体内缓解大鼠肺动脉高压。
核心结论
- A2B1是PAH-PASMC表型的主调控因子,并可作为PAH的治疗靶点。
研究设计与样本
- 研究整合计算与实验生物学,在人类PAH-PASMC中探究A2B1功能。
- 采用生物信息学和RNA测序研究A2B1的全转录组功能,通过RNA免疫沉淀和A2B1沉默实验解析分子机制。
- 在野百合碱诱导的肺动脉高压大鼠模型中进行临床前试验,评估抑制A2B1对减轻肺动脉高压严重程度的作用。
主要发现
- 人类PAH-PASMC中A2B1表达及其核定位增加。
- 生物信息学鉴定出A2B1的3个已知基序及所有携带这些基序的mRNA。
- 在PAH-PASMC中,A2B1的3个基序均参与细胞周期的不同方面,显示互补非冗余功能。
- 在PAH-PASMC中,A2B1促进其靶标mRNA的表达。
- PAH-PASMC中沉默A2B1导致所有携带A2B1基序的测试mRNA减少,同时增殖减少和抗凋亡能力下降。
临床怎么用
- A2B1可能作为PAH的潜在治疗靶点,但需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: RNA-binding proteins are master orchestrators of gene expression regulation. They regulate hundreds of transcripts at once by recognizing specific motifs. Thus, characterizing RNA-binding proteins targets is critical to harvest their full therapeutic potential. However, such investigation has often been restricted to a few RNA-binding protein targets, limiting our understanding of their function. In cancer, the RNA-binding protein HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2B1; A2B1) promotes the pro-proliferative/anti-apoptotic phenotype. The same phenotype in pulmonary arterial smooth muscle cells (PASMCs) is responsible for the development of pulmonary arterial hypertension (PAH). However, A2B1 function has never been investigated in PAH. METHOD: Through the integration of computational and experimental biology, the authors investigated the role of A2B1 in human PAH-PASMC. Bioinformatics and RNA sequencing allowed them to investigate the transcriptome-wide function of A2B1, and RNA immunoprecipitation and A2B1 silencing experiments allowed them to decipher the intricate molecular mechanism at play. In addition, they performed a preclinical trial in the monocrotaline-induced pulmonary hypertension rat model to investigate the relevance of A2B1 inhibition in mitigating pulmonary hypertension severity. RESULTS: They found that A2B1 expression and its nuclear localization are increased in human PAH-PASMC. Using bioinformatics, they identified 3 known motifs of A2B1 and all mRNAs carrying them. In PAH-PASMC, they demonstrated the complementary nonredundant function of A2B1 motifs because all motifs are implicated in different aspects of the cell cycle. In addition, they showed that in PAH-PASMC, A2B1 promotes the expression of its targets. A2B1 silencing in PAH-PASMC led to a decrease of all tested mRNAs carrying an A2B1 motif and a concomitant decrease in proliferation and resistance to apoptosis. Last, in vivo A2B1 inhibition in the lungs rescued pulmonary hypertension in rats. CONCLUSIONS: Through the integration of computational and experimental biology, the study revealed the role of A2B1 as a master orchestrator of the PAH-PASMC phenotype and its relevance as a therapeutic target in PAH.
引用
- Ruffenach G, Medzikovic L, Aryan L, et al. HNRNPA2B1: RNA-Binding Protein That Orchestrates Smooth Muscle Cell Phenotype in Pulmonary Arterial Hypertension. Circulation. 2022. PMID: 35993245. doi:10.1161/CIRCULATIONAHA.122.059591
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。